| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $19.0M | — | +38.7% |
| SG&A Expense | $10.6M | — | +77.5% |
| Operating Income | -$29.6M | — | -50.6% |
| Net Income | -$26.8M | — | -62.5% |
| EPS (Basic) | -$0.60 | — | +99.9% |
| EPS (Diluted) | -$0.60 | — | +99.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $63.3M | +8.3% | -23.4% |
| Current Assets | $221.0M | -8.5% | -19.3% |
| Total Assets | $305.0M | -6.4% | -17.5% |
| Current Liabilities | $9.8M | -16.5% | +2.6% |
| Total Liabilities | $16.8M | -12.0% | -6.0% |
| Stockholders' Equity | $288.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.8M | — | -34.1% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $24.8M | — | +117.6% |
| Financing Cash Flow | $1.9M | — | -99.1% |
| Free Cash Flow | -$21.8M | — | -33.4% |
| -18.1% |